- TRADE NAME: Zykadia (Novartis)
- INDICATIONS: Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor
- HALF-LIFE: 41 hours
- FDA APPROVAL DATE: 04/29/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Carbamazepine, Cyclosporine, CYP3A and CYP2C9 substrates, Dihydroergotamine, Ergotamine, Fentanyl, Grapefruit Juice, Ketoconazole, Nefazodone, Phenytoin, Pimozide, Quinidine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Strong CYP3A inhibitors and inducers, Tacrolimus, Telithromycin, Warfarin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
